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Abstract
The down-regulation of the tumor-suppressor gene RASSF1A has been shown to increase cell proliferation in several tumors.
RASSF1A expression is regulated through epigenetic events involving the polycomb repressive complex 2 (PRC2); however,
the molecular mechanisms modulating the recruitment of this epigenetic modifier to the RASSF1 locus remain largely
unknown. Here, we identify and characterize ANRASSF1, an endogenous unspliced long noncoding RNA (lncRNA) that is
transcribed from the opposite strand on the RASSF1 gene locus in several cell lines and tissues and binds PRC2. ANRASSF1 is
transcribed through RNA polymerase II and is 59-capped and polyadenylated; it exhibits nuclear localization and has a
shorter half-life compared with other lncRNAs that bind PRC2. ANRASSF1 endogenous expression is higher in breast and
prostate tumor cell lines compared with non-tumor, and an opposite pattern is observed for RASSF1A. ANRASSF1 ectopic
overexpression reduces RASSF1A abundance and increases the proliferation of HeLa cells, whereas ANRASSF1 silencing
causes the opposite effects. These changes in ANRASSF1 levels do not affect the RASSF1C isoform abundance. ANRASSF1
overexpression causes a marked increase in both PRC2 occupancy and histone H3K27me3 repressive marks, specifically at
the RASSF1A promoter region. No effect of ANRASSF1 overexpression was detected on PRC2 occupancy and histone
H3K27me3 at the promoter regions of RASSF1C and the four other neighboring genes, including two well-characterized
tumor suppressor genes. Additionally, we demonstrated that ANRASSF1 forms an RNA/DNA hybrid and recruits PRC2 to the
RASSF1A promoter. Together, these results demonstrate a novel mechanism of epigenetic repression of the RASSF1A tumor
suppressor gene involving antisense unspliced lncRNA, in which ANRASSF1 selectively represses the expression of the
RASSF1 isoform overlapping the antisense transcript in a location-specific manner. In a broader perspective, our findings
suggest that other non-characterized unspliced intronic lncRNAs transcribed in the human genome might contribute to a
location-specific epigenetic modulation of genes.
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Introduction
RASSF1A (RAS-association domain family member 1A) is a
tumor suppressor gene that modulates a broad range of cellular
functions essential for normal growth, such as the maintenance
of genomic stability, cell cycle control, the modulation of
apoptosis, and cell motility and invasion [1]. RASSF1A is one of
seven alternatively spliced isoforms (RASSF1A to G) generated at
the gene locus through the differential usage of two promoters
or alternative splicing [2,3]. The biological relevance of only
two isoforms, RASSF1A and RASSF1C, has been demonstrated.
Both isoforms are ubiquitously expressed in non-tumor tissues,
whereas in tumors and tumor cell lines, the expression of
RASSF1A is frequently low, leading to increased cell prolifera-
tion [3]. RASSF1A promoter CpG island hypermethylation and
reduced gene expression are frequently observed in a wide range
of cancers [4–9]. The epigenetic silencing of RASSF1A requires
the HOXB3-mediated induction of DNMT3B DNA methyl-
transferase expression and the recruitment of the DNMT3B
protein to the RASSF1A promoter [10]. The recruitment of
DNMT3B and the polycomb repressor complex 2 (PRC2) is
dependent on MYC proto-oncogene protein, which is bound to
the RASSF1A promoter [10]. Although MYC is required for
PRC2 recruitment to the RASSF1A promoter [10], MYC is
generally not sufficient to recruit PRC2 [10,11], and other
regulatory factors and mechanisms underlying the recruitment
of this epigenetic silencing machinery have not yet been
identified.
The human genome encodes thousands of long (.200 nt)
noncoding RNAs (lncRNAs) [12,13] that might function via
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diverse mechanisms [14–16]. Intergenic lncRNAs have been
associated with gene silencing through guiding enzymes
involved in chromatin remodeling, particularly PRC2, causing
the posttranslational modification of histones in target genes
[17–19]. In addition, recent reports have shown that thousands
of lncRNAs are associated with PRC2 and that many of these
are sense and antisense intronic lncRNAs [20,21], not
intergenic.
In the present study, we identified a novel unspliced antisense
intronic lncRNA, ANRASSF1, which is expressed in the RASSF1
gene locus independently from the protein-coding gene. The
modulation of ANRASSF1 abundance through ectopic overexpres-
sion or transient knockdown affected the expression level of
RASSF1A, with no effect on RASSF1C. We demonstrated that
ANRASSF1 formed an lncRNA/DNA hybrid, which mediated the
recruitment of SUZ12, a member of PRC2, to the RASSF1A
promoter. The recruitment of SUZ12 resulted in a marked
increase in the H3K27me3 levels only at the RASSF1A promoter
region, without accumulation of the repressive mark either at the
RASSF1C promoter or the four neighboring loci. ANRASSF1-
mediated gene repression occurred in a highly location-specific
manner, as only the RASSF1A isoform, which overlaps the
antisense transcript, was affected.
Results
ANRASSF1 is transcribed antisense to the RASSF1A gene
We surveyed the public Expressed Sequence Tags (ESTs)
database and identified a long RNA transcript that mapped to an
intronic region of the RASSF1 genomic locus. This transcript was
represented by a cluster of ESTs covering 580 bp of the genome,
which mapped just upstream of the RASSF1C isoform (Figure 1A,
light gray rectangle) and overlapped exon 2 of RASSF1A. Indeed,
this transcript was one of 67,731 putative unspliced lncRNAs
mapping to intronic regions of 74% of all protein-coding genes,
which were previously described by our group [22], being part of a
genome-wide pervasive lncRNA expression involving between 75
and 90% of the human genome [12,13,23].
The ESTs described above originated from non-strand specific
cDNA libraries produced from a number of different human
tissues, and we used strand-oriented RT-PCR to confirm the
expression of this long RNA in several cell lines. Figure 1B shows
the expression of an RNA transcribed in the antisense direction
relative to protein-coding mRNAs encoded in the RASSF1 locus in
nine different cell lines. This transcript will hereafter be referred to
as ANRASSF1, for Antisense Intronic Noncoding RASSF1 RNA.
Next, we used the Rapid Amplification of cDNA Ends (RACE)
approach to extend both the 59 and 39 ends of the ANRASSF1
transcript. The 39 RACE-PCR product was sequenced, showing a
38-nt extension beyond the existing ESTs, with 5 nt of the
extended sequence matching the genome and the additional
sequence showing a poly(A) tail of 33 adenines (Figure 1A). We
also identified a conserved polyadenylation signal (ATTAAA) [24]
17 nt upstream of the poly(A) tail. Using a combined approach
involving 59 RACE-PCR with primer-walking PCR and sequenc-
ing, we extended the transcript 205 nt at the 59 end (Figure 1A,
red box), resulting in a full-length ANRASSF1 transcript of 790 nt.
High-throughput strand-specific RNA-seq of poly(A)+ RNA from
LNCaP prostate cancer cells showed transcription from the plus
strand in the RASSF1 locus (Figure 1C), and the assembly of these
RNA-seq reads using the Cufflinks tool generated a consensus
sequence mapping to the genomic plus strand in the locus. These
data essentially confirmed the length and antisense orientation of
ANRASSF1, which were previously identified through strand-
specific RT-PCR, RACE-PCR and sequencing. Using the Coding
Potential Calculator tool [25], no coding potential was predicted
for the full-length ANRASSF1, confirming ANRASSF1 as an
lncRNA.
Because ANRASSF1 is represented by an Affymetrix probe set in
the HG-U133 Plus2 microarray platform and the entire RASSF1
locus is represented by a different probe set, we performed a meta-
analysis of the ANRASSF1 and RASSF1 expression patterns on
publicly available microarray data. We identified a statistically
significant inverse correlation (Figure 1D) between the expression
levels of ANRASSF1 and RASSF1 in HeLa, MDA-MB-231 and
MCF-7 cells, which are three cell lines in which we had previously
confirmed ANRASSF1 expression using RT-PCR (Figure 1B). In
addition, this meta-analysis revealed that in Jurkat cells under
mitotic stress (Figure 1E), RASSF1 showed a 1.5-fold increase
within the first hour following mitogen stimulation with a phorbol
ester and ionomycin; this response was inversely correlated with
ANRASSF1 expression. Notably, the expression of RASSF1 and
Daxx was described to define a mitotic stress checkpoint that
enables cells to exit mitosis and eventually die [26]. Our meta-
analysis also detected an inverse correlation between ANRASSF1
and RASSF1 in three other studies using cell lines and human
tissue samples (Figure S1). Overall, these data highlight a
functional role for ANRASSF1 in the host locus.
Inverse correlation between ANRASSF1 and RASSF1A
expression in non-tumor and tumor cell lines
Next, we measured ANRASSF1 and RASSF1A expression in
tumor and non-tumor immortalized cell lines obtained from the
breast (Figure 2A) and prostate (Figure 2B). Interestingly, we
detected the reduced expression of ANRASSF1 in non-tumor cell
lines compared with tumors in both tissues, and an opposite
pattern for RASSF1A expression, which was higher in non-tumor
cells compared with tumor cell lines. Thus, the inverse correlation
between ANRASSF1 and RASSF1 expression in the public array
datasets was confirmed in the one non-tumor and two tumor cell
lines obtained from two different tissues.
Author Summary
RASSF1A is a tumor suppressor gene whose expression is
repressed through epigenetic events in a wide range of
different cancers. Repression is effected by DNA hyper-
methylation of the RASSF1A promoter, which in turn is
triggered through histone H3K9/H3K27 trimethylation
repressive marks. The addition of the H3K27me3 mark at
the RASSF1A promoter locus involves the polycomb
repressive complex 2 (PRC2). The molecular mechanisms
that control the recruitment of PRC2 to the promoter to
initiate H3K27 trimethylation and repress RASSF1A expres-
sion have not been described. Here, we identified a long
noncoding RNA (lncRNA), termed ANRASSF1 for antisense
noncoding RASSF1, that is transcribed from the opposite
strand of the RASSF1A gene and is responsible for
recruiting PRC2 to the RASSF1A promoter region in a
highly location-specific manner. No effect of ANRASSF1
was detected on the promoter of the RASSF1C isoform or
the promoters of the four other genes within the vicinity of
RASSF1, including two other well-characterized tumor
suppressor genes. This work provides evidence that the
epigenetic modulation of the tumor suppressor gene
RASSF1A is dependent on the lncRNA ANRASSF1 and
highlights the importance of further studies on the
involvement of ANRASSF1 in tumorigenesis.
lncRNA ANRASSF1 Modulates RASSF1A Expression
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Figure 1. Antisense noncoding RNA ANRASSF1 is expressed within the RASSF1 genomic locus and inversely correlated with RASSF1
expression. (A) Schematic representation of the entire RASSF1 locus presented at the top. Protein-coding RASSF1 gene isoforms (RefSeq-annotated)
are shown in black; ANRASSF1 evidence from an assembly of public ESTs is shown in light gray; the portions extended through 59-end RACE and
primer-walking or 39-end RACE are shown in red, with a poly(A) segment detected through sequencing. The arrowheads define the orientation of the
sequences. (B) ANRASSF1 was detected in several human cell lines using end-point PCR in the antisense (AS), and not the sense (S), direction relative
to the protein-coding gene. Strand-specific primers were used for the reverse-transcription (RT) (short half-arrow numbers 2 and 3 on ANRASSF1 in
panel A). RT reaction in the absence of primer was used as a negative control (Ctl). The short half-arrows numbered 1 and 4 indicate the primers used
for the end-point PCR. (C) Strand-specific RNA-seq from poly(A)+ RNA of LNCaP cells. The abundance of the reads mapping within the RASSF1
genomic locus is displayed in the diagram, and the color corresponds to the DNA strand of the transcripts. The red horizontal bar represents the
consensus sequence from the assembly of RNA-seq reads mapping to the positive strand in this locus, generated using the Cufflinks tool. The gray
bar represents the full-length ANRASSF1, obtained by RACE-PCR and Sanger sequencing. The arrowheads define the orientation of the sequences. (D)
Expression of RASSF1 and ANRASSF1 measured with Affymetrix microarrays in HeLa, MDA-MB-231 and MCF-7 cells from GSE5823 [54]. (E) The
expression of RASSF1 and ANRASSF1 measured with Affymetrix microarrays in Jurkat cells under mitotic stress induced through treatment with
phorbol ester and ionomycin for 30 and 60 min from GSE11118 [55].
doi:10.1371/journal.pgen.1003705.g001
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ANRASSF1 lncRNA is RNAPII-encoded and
nuclear-enriched and has a short half-life
To determine whether ANRASSF1 lncRNA is transcribed
through RNA Polymerase II, we treated HeLa cells with a-
amanitin at a concentration of 10 mg/mL, which inhibits only
RNAPII. Figure S2A shows that ANRASSF1 transcription was
abolished in a-amanitin-treated cells.
ANRASSF1 contained a 59 end methyl-guanosine cap modifica-
tion, as shown by its resistance to 59-exonucleolytic digestion in
vitro (Figure S2B). To determine ANRASSF1 stability, HeLa cell
cultures were treated for 1 to 8 h with the RNA polymerase
inhibitor actinomycin D. ANRASSF1 levels decayed with a half-life
of ,50 min following transcriptional inhibition (Figure S2C). For
comparison, c-Myc mRNA displayed a half-life of ,20 min under
similar conditions (Figure S2C).
Nuclear and cytoplasmic total RNA fractions were prepared
from HeLa cells, and the relative abundance of ANRASSF1 was
measured using qPCR. Figure S2D shows that ANRASSF1 was
100-fold enriched in the nuclear fraction relative to the cytoplasm.
A comparison of the expression levels of ANRASSF1 with those
of abundant intergenic lncRNAs (lincRNAs), such as MALAT1
[27], HOTAIR [19] and lincRNA SFPQ [18] showed that
endogenous ANRASSF1 was much less abundant (approximately
500- to 1,000-fold lower) than these lincRNAs in HeLa cells
(Figure S2E). Similarly, endogenous ANRASSF1 was approximate-
ly 500- to 1,000-fold less abundant than the protein-coding
RASSF1A and RASSF1C mRNAs, which are expressed from the
same host locus (Figure S2E), demonstrating that ANRASSF1 was
expressed at low levels in the cell.
ANRASSF1 is transcribed from an independent promoter
A putative bidirectional promoter region spanning the tran-
scription start-sites of ANRASSF1 and RASSF1C has been predicted
in silico [28]. We referred to the region on the genomic plus strand
upstream of ANRASSF1 as the ‘‘antisense promoter’’ and the
region in the minus strand upstream of RASSF1C as the ‘‘sense
promoter’’ (Figure S3A). The activity of both promoters was
measured in vitro, and both promoters showed a significant
induction of the firefly luciferase reporter relative to the control
(p,0.01) (Figure S3B). This result confirmed the presence of a
bidirectional promoter, specifically indicating promoter activity
upstream of the ANRASSF1 lncRNA, thus supporting an
independent antisense transcriptional unit in this locus.
Overexpression of ANRASSF1 negatively modulates the
protein-coding RASSF1A mRNA and decreases the
RASSF1A protein
The observation of an inverse correlation between ANRASSF1
and RASSF1 expression (Figures 1D, 1E, 2 and S1) prompted us to
determine whether ANRASSF1 could act in cis to modulate the
expression of the protein-coding gene in the same locus. We
overexpressed ANRASSF1 and subsequently measured the levels of
the RASSF1 transcript isoforms. When the expression levels of
ANRASSF1 were increased to 40-fold compared with the control
cells (Figure 3A), RASSF1A expression was significantly decreased
to 21% of its endogenous level (Figure 3B). Interestingly, the
overexpression of ANRASSF1 did not affect the abundance of the
RASSF1C mRNA isoform (Figure 3C).
In parallel, the levels of RASSF1A protein were determined
through western blot. Figure 3D shows that RASSF1A was
reduced in pCEP4 ANRASSF1-transfected HeLa cell lines com-
pared with control cells. Densitometric analysis of western blots
from three replicates of cells overexpressing ANRASSF1 showed a
57% decrease in the levels of RASSF1A protein compared with
the normal levels observed in the control cells (Figure 3E).
Overexpression of ANRASSF1 increases the cell
proliferation rate and decreases cell death
To determine whether the decrease in RASSF1A protein due to
overexpression of ANRASSF1 would result in detectable pheno-
typic changes, cell-proliferation assays were performed. First, we
observed that cells overexpressing ANRASSF1 proliferated at a
significantly faster rate than the control cells (Figure 4A), with a
significant 22% average increase in the proliferation rate (p,0.03)
determined using an MTS assay. We also measured cell
population growth by directly counting the number of cells over
time in culture in a Neubauer chamber (Figure 4B); the adjusted
exponential growth functions (R2 ranging from 0.93 to 0.99
Figure 2. Inverse correlation between ANRASSF1 and RASSF1A expression in non-tumor and tumor cell lines. Expression of ANRASSF1
and of RASSF1A in (A) breast and (B) prostate cell lines. Tumor cell lines (white bars) and non-tumor immortalized cell lines (hatched bars) were tested.
These data show the means 6 SD from two or three independent biological replicates for each cell line. The expression values in tumors are shown
compared with the expression in the non-tumor cell line. These data are calculated relative to HPRT1 expression.
doi:10.1371/journal.pgen.1003705.g002
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throughout the replicates) showed calculated doubling times of
20.261.9 and 25.063.7 h for the cells overexpressing ANRASSF1
and the control cells, respectively, with a significant 24% average
increase in the cell growth rate (p,0.05) upon ANRASSF1
overexpression (Figure 4B). The 22 to 24% increase in cell
proliferation rate observed in the MTS and cell number counting
assays upon the increase in ANRASSF1 expression, with a resulting
decrease of RASSF1A abundance, is consistent with the tumor
suppressor function of this protein. This increase is comparable to
the 26% increase in cell proliferation over one day previously
observed with RASSF1A siRNA [29].
In addition to reducing cell proliferation, RASSF1A exerts a
proapoptotic signaling function [30]. We therefore measured the
cell death caused by exposure to UVC light or the cytotoxic anti-
cancer drug staurosporine to determine whether the overexpres-
sion of ANRASSF1 and the resulting decrease in RASSF1A would
affect the course of cell death. Figure 4C shows that UVC
irradiation (40 J/m2) caused an important increase in cell death, as
shown by the increase in the sub-G1 population of cells, and the
overexpression of ANRASSF1 substantially decreased the UVC-
induced sub-G1 population, which is indicative of a reduction in
cell death. Figure 4D shows the average increase in the sub-G1
population in the control cells (empty pCEP4) exposed to UVC
compared with no-UV, as measured in three independent replicas,
and a significant decrease in the percentage of the sub-G1
population in cells overexpressing ANRASSF1 after exposure to
UVC (t-test p,0.05), which is indicative of reduced cell death in the
latter condition compared with the control (empty pCEP4) cell line.
Next, we measured cell death in response to the cytotoxic drug
staurosporine (100 nM), a classical initiator of apoptosis by both
caspase-dependent and caspase-independent pathways [31], and
again tested the effect of ANRASSF1 overexpression on cell death.
We employed the xCELLigence platform microelectric assay
based on the changing impedance of electrodes in the presence of
live cells to examine the drug-induced cytotoxicity over an
extended period of time in culture (170 h). Figure 4E shows that
after exposure to staurosporine for 96 h, the cells overexpressing
ANRASSF1 were considerably more resistant to death, remaining
attached to the culture plates, even after 170 h; the measured cell
index, which corresponded with the number of live cells attached
to the plate (Figure 4E), showed a significant 4.2-fold average
increase in cells overexpressing ANRASSF1 compared with the
control cells (empty pCEP4) at 170 h in the three biological
replicates (p,0.001). These findings are consistent with the
proapoptotic signaling function of RASSF1A [30] and indicate
that RASSF1A silencing through the overexpression of ANRASSF1
attenuated the cell death signal induced through UVC irradiation
or staurosporine treatment.
Figure 3. Overexpression of ANRASSF1 decreases the protein-coding RASSF1A isoform. (A) Expression of ANRASSF1 in HeLa cells
transfected with the ANRASSF1-containing vector (pCEP4 ANRASSF1) compared with ANRASSF1 expression in control HeLa cells transfected with an
empty vector (empty pCEP4). Relative expression detected using RT-qPCR; these data are plotted relative to a-tubulin. These data show the means6
SD from three independent replicate transfection experiments. *p,0.01 relative to control. (B) Relative expression of RASSF1A isoform in ANRASSF1-
transfected and control cells, as described in (A). These data show the means 6 SD from three independent transfection experiments. *p,0.01
relative to control. (C) Relative expression of the RASSF1C isoform in ANRASSF1-transfected and control cells, as described in (A). These data show the
means 6 SD from three independent transfection experiments. (D) Western blot analysis using an antibody against RASSF1A protein in the lysates
obtained from control HeLa cells (empty pCEP4) or ANRASSF1-transfected cells (pCEP4 ANRASSF1). An antibody against actin was used as control. (E)
Densitometric analyses of the RASSF1A western blot signals from three replicate assays. Relative protein levels of RASSF1A normalized to actin. These
data show the means 6 SD from three independent transfection experiments. *p,0.02.
doi:10.1371/journal.pgen.1003705.g003
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ANRASSF1 silencing positively modulates the protein-
coding RASSF1A message levels
To further document the effect of ANRASSF1 abundance on the
expression of RASSF1A, we designed specific siRNAs to silence
ANRASSF1. A pool of three different siRNAs targeting ANRASSF1
significantly reduced ANRASSF1 expression to 39% of its
endogenous level compared with a scrambled siRNA control
(Figure 5A). Concomitantly, we observed a 2.25-fold increase in
the relative abundance of RASSF1A mRNA (Figure 5B). The
decrease in ANRASSF1 expression did not affect the abundance of
the RASSF1C isoform (Figure 5C), which is consistent with the lack
of effect of ANRASSF1 overexpression on RASSF1C previously
observed.
Next, we performed cell-proliferation assays to determine
whether ANRASSF1 knockdown and the consequent increase in
the RASSF1A mRNA levels affected the cell proliferation rate. We
observed that cells with silenced ANRASSF1 expression proliferated
at a significantly slower rate than control cells (Figure 5D), with an
Figure 4. Overexpression of ANRASSF1 increases cell growth and decreases UVC- and staurosporine-mediated cell death. (A) Cell
proliferation coefficients of ANRASSF1-transfected cells (pCEP4 ANRASSF1) relative to control cells (empty pCEP4), as measured using MTS assay. These
data show the means 6 SD from three independent experiments. *t-test p,0.03 relative to control. (B) Effect of ANRASSF1 overexpression on the cell
population growth, as measured by counting the number of cells over time in culture and calculating the population doubling time. These data show
the means 6 SD from two independent experiments in triplicate. * t-test p,0.05. (C) DNA content histograms showing the effect of ANRASSF1
overexpression on the cell cycle at 48 h after exposure to UVC irradiation (40 J/m2). The cells were labeled with propidium iodide. Light gray indicates
the sub-G1 population. (D) Percent of sub-G1 population from experiments identical to (C). These data show the means6 SD from three independent
replicate experiments. *t-test p,0.05 relative to control. (E) Effect of ANRASSF1 overexpression on cell survival in the presence of the cytotoxic drug
staurosporine (100 nM). The changes in impedance were measured using the xCELLigence system to continuously monitor cell attachment to the
culture plates. Three independent biological replicates for either condition (pCEP4 ANRASSF1 or empty pCEP4) are shown, each representing the
means 6 SD of two or three technical replicates; the red lines show cells overexpressing ANRASSF1, and the blue lines show control cells carrying
empty pCEP4) vector. *t-test p,0.001, for the cell indices at 170 h.
doi:10.1371/journal.pgen.1003705.g004
lncRNA ANRASSF1 Modulates RASSF1A Expression
PLOS Genetics | www.plosgenetics.org 6 August 2013 | Volume 9 | Issue 8 | e1003705
average 15% decrease in the proliferation rate compared with
control cells (p,0.02).
Accumulation of histone H3K27 trimethylation to the
RASSF1A promoter locus is dependent on the level of
ANRASSF1 binding to PRC2
We sought to gain mechanistic insight into the involvement of
the lncRNA ANRASSF1 in regulating RASSF1A expression.
ANRASSF1 has nuclear localization, suggesting that this protein
might be involved in the recruitment of other factors (MYC/
PRC2) involved in RASSF1A gene silencing through H3K27
trimethylation and/or DNA promoter methylation [10].
First, we examined whether endogenous ANRASSF1 was
physically associated with PRC2 using a native non-cross linked
RNA immunoprecipitation (RNA-IP) with an antibody specific to
SUZ12, a member of the PRC2 complex. Figure 6A shows that
the endogenous ANRASSF1 was 5.3-fold enriched with respect to
negative control RNA, which was not expected to bind PRC2,
namely GAPDH mRNA. The endogenous lincRNA SFPQ, which
binds PRC2, as determined with anti-SUZ12 and anti-EZH2
antibodies [18], was used as positive control and showed a 2.8-fold
enrichment (Figure 6B).
Using an antibody specific to EZH2, another member of the
PRC2 complex (Figure S4), we observed that endogenous
ANRASSF1 was enriched in the anti-EZH2 RNA-IP fraction
relative to the input compared with the IgG fraction.
Next, we determined whether the PRC2 complex was bound to
the promoter region of RASSF1A and if the overexpression of
ANRASSF1 affects PRC2 occupancy in this region. We performed
chromatin immunoprecipitation (ChIP) using an anti-SUZ12
antibody and observed a significant 8-fold increase of the RASSF1A
promoter DNA bound to PRC2 in cells overexpressing ANRASSF1
compared with control cells expressing endogenous levels of
ANRASSF1 (Figure 6C). Interestingly, no significant change in
PRC2 occupancy upon ANRASSF1 overexpression was observed
either at the promoter region of the RASSF1C isoform or the
promoter of the four neighboring genes, two on either side at the
RASSF1 locus (Figure 6C), including the two well-characterized
tumor suppressor genes TUSC2 [32] and NPRL2 [33]. As
additional controls, no significant change was detected at either
the promoter of GAPDH, a gene not regulated through SUZ12, or
the promoter of HOXA9, a gene regulated through SUZ12 [34]
and encoded in chromosome 7, away from the RASSF1 locus in
chromosome 3. These results indicate a correlation between the
higher levels of ANRASSF1 and the higher PRC2 occupancy at the
RASSF1A promoter.
PRC2 is a histone-modifying enzyme complex responsible for
adding di- and trimethylation marks onto H3K27. We determined
whether ANRASSF1 overexpression, which increases PRC2
occupancy, also affected the level of H3K27me3 at the RASSF1A
promoter region. Figure 6D shows that there was a 5.1-fold
enrichment of the RASSF1A promoter DNA associated with
histone H3K27me3 when ANRASSF1 was overexpressed com-
pared with control cells with endogenous levels of ANRASSF1,
confirming that H3K27 trimethylation in the RASSF1A promoter
is dependent on the level of ANRASSF1 binding to PRC2. No
significant changes in H3K27me3 were observed at either the
promoter region of RASSF1C or the promoter region of the four
other genes in the vicinity of RASSF1 (Figure 6D). In addition, no
change was detected at the promoter region of HOXA9. These
results suggest highly location-specific epigenetic modulation.
Because DNA methylation of the RASSF1A promoter involves
PRC2 and DNMT3B [10], we examined whether the increased
recruitment of PRC2 through ANRASSF1 overexpression also
affected DNMT3B occupancy at the RASSF1A promoter or DNA
methylation at the locus. Figure 6E shows that the DNMT3B
occupancy at the RASSF1A promoter is not affected by ANRASSF1
overexpression in HeLa cells. A methylation-dependent endonu-
clease assay showed no significant effect on the DNA methylation
at the promoter region of RASSF1A in cells overexpressing
ANRASSF1 compared with the control (Figure 6F).
ANRASSF1 is bound to DNA and required for the PRC2
occupancy at the RASSF1A promoter
Recent reports have shown that lincRNAs, such as
lncRNACCND1 [35] and Mistral [36], bind to DNA and recruit
proteins that act at the promoter regions of neighboring protein-
coding genes to regulate their expression. We determined whether
ANRASSF1 might act in a similar manner through binding to DNA
and recruiting the PRC2 complex in cis to the promoter of
Figure 5. ANRASSF1 knockdown increases the RASSF1A isoform expression and decreases cell proliferation. (A) Expression levels of
ANRASSF1 in cells treated with siRNA ANRASSF1 relative to the expression of ANRASSF1 in control cells treated with scrambled siRNA (siRNA control).
The relative expression was detected using RT-qPCR normalized to a-tubulin. These data show the means6 SD from three independent experiments.
*p,0.01 relative to control. (B) The relative expression levels of RASSF1A in siRNA ANRASSF1 cells and siRNA control cells, as described in (A). These
data show the means 6 SD from three independent experiments. *p,0.01 relative to the control. (C) The relative expression levels of RASSF1C in
siRNA ANRASSF1 cells and siRNA control cells, as described in (A). (D) Cell proliferation coefficients of siRNA ANRASSF1 cells relative to the control cells
(siRNA control). These data show the means 6 SD from three independent experiments. *p, 0.02 relative to control.
doi:10.1371/journal.pgen.1003705.g005
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RASSF1A. For this purpose, we treated permeabilized HeLa cells
with RNase H to deplete endogenous ANRASSF1 associated with
DNA, followed by ChIP using an anti-SUZ12 antibody. First, we
measured the endogenous ANRASSF1 levels in cells treated either
with RNase inhibitor (Figure 7A, black bar) or RNase H
(Figure 7A, red bar). With RNase H treatment, which digests
RNA/DNA hybrids, the ANRASSF1 level was reduced to 13%,
suggesting that ANRASSF1 is part of an RNA/DNA hybrid.
Alpha-tubulin RNA, which was used as a control in this study, was
only digested by RNase A (Figure 7B, blue bar), not RNase H
(Figure 7B, red bar), as anticipated for an RNA that is not
expected to form RNA/DNA hybrids. In parallel, we measured
the PRC2 occupancy at the RASSF1A and RASSF1C promoter
regions and observed that the maximum occupancy was obtained
in the presence of RNase inhibitor (Figure 7C and 7D, black bars).
Treatment with RNase H resulted in an almost total release of
PRC2 from the RASSF1A promoter region (Figure 7C, red bar),
while a low PRC2 occupancy at the RASSF1C promoter region
(Figure 7D, black bar) and no significant reduction upon RNase H
or RNase A treatment was observed (Figure 7D, red and blue
bars); these data indicate that the PRC2 occupancy at the
RASSF1A promoter region — not the RASSF1C promoter region
— is driven by ANRASSF1.
We also performed an RNase-ChIP assay using an anti-
DNMT3B antibody, and no differences in the occupancy at the
RASSF1A or RASSF1C promoter regions were detected under
RNase H or RNase A treatments (Figure 7E and 7F). This result
indicates that the DNMT3B occupancy at the RASSF1 locus is not
driven by ANRASSF1; consistent with the observation described
above, the DNMT3B occupancy at the RASSF1A promoter was
not affected through ANRASSF1 overexpression (Figure 6E).
Finally, a negative control RNase-ChIP with anti-RNA Pol II,
a factor whose occupancy at the promoters of RASSF1A and
RASSF1C is not expected to be affected by RNase H treatment,
was included; treatment with RNase H or RNase A did not
change the RASSF1A or RASSF1C promoter occupancy by RNA
Pol II (Figure 7G and 7H), ruling out the notion that the effect
on PRC2 would result from the toxic effect of RNase treatment
on the cells.
Notably, in cells treated with RNase A, which digests single-
stranded RNA (ssRNA), we observed both a reduction in the
endogenous ANRASSF1 (Figure 7A, blue bar) and the PRC2
occupancy at the RASSF1A promoter (Figure 7C, blue bar);
however, the reduction was considerably smaller than that
obtained with RNase H treatment (see Figure 7A and 7C, red
bars), suggesting that the ssRNA in the nucleoplasm was in rapid
equilibrium with the RNA/DNA hybrids and that a shift from
hybrids to single-strand occurred as the hybrid was digested.
Alternatively, there could be two distinct populations of ssRNA
and RNA-DNA hybrids, and both could play a role in the
association of PRC2 with chromatin.
A similar pattern of RNase H digestion and PRC2 occupancy at
the RASSF1A promoter was observed in cells overexpressing
ANRASSF1 (Figure S5). Notably, the amount of ANRASSF1
under overexpression conditions was 40-fold higher than that
endogenously expressed (see Figure 3A); therefore, the similar
percentage of ANRASSF1 depletion achieved through RNase H
treatment (Figure S5B) indicates that the absolute amount of the
remaining ANRASSF1 was also approximately 40-fold higher in
overexpressing cells, resulting in a smaller reduction of PRC2
binding at the RASSF1A promoter in overexpressing cells treated
with RNase H (45% reduction with respect to the inhibitor,
Figure S5A) compared with cells with endogenous lncRNA
treated with RNase H (90% reduction with respect to the
inhibitor, Figure 7C).
RNAi was employed to determine whether the reduction of
PRC2 occupancy at the RASSF1A promoter is specifically
associated with ANRASSF1 expression. The knockdown of
ANRASSF1 to 40% of the endogenous level (data not shown)
caused a 55% reduction in PRC2 occupancy at the RASSF1A
promoter (Figure 8A). Similarly, Palakurthy et al. [10] knocked
down EZH2 expression using RNAi and observed an increase in
the expression of RASSF1A. Taken together, these results indicate
that the recruitment of PRC2 complex to the promoter of
RASSF1A specifically relies on the association of PRC2 with an
ANRASSF1/DNA hybrid structure.
In parallel, we also measured the DNMT3B occupancy and
levels of DNA methylation at the RASSF1A promoter (Figure 8B
and 8C); neither condition was affected by ANRASSF1 knockdown,
which is consistent with our observations of a lack of effect on
DNMT3B occupancy when ANRASSF1 was either overexpressed
or digested by RNase.
Discussion
Some of the features identified for ANRASSF1, such as the
presence of a 59 cap, transcription through RNAPII, nuclear
enrichment and binding to PRC2, are shared with other lncRNAs
[18,37]. However, the ANRASSF1 half-life is short (,50 min)
compared with other moderately stable lncRNAs that exert
epigenetic roles, such as Air, Kcnq1ot1 and Xist, which have half-
lives of 2.1, 3.4 and 4.6 h, respectively [38].
Figure 6. ANRASSF1 interacts with PRC2 and affects its occupancy at the RASSF1A promoter. (A) Endogenous ANRASSF1 levels bound to
PRC2 were measured in HeLa cells through RNA IP with anti-SUZ12 relative to the input. A control IP with non-specific IgG was performed in parallel.
As a negative control, GAPDH mRNA, which was not expected to bind to PRC2, was used. The percent input in the IP fractions was shown as the
ANRASSF1/GAPDH ratio. These data show the means 6 SD from three independent experiments. (B) lincRNA SFPQ is a positive control that binds to
PRC2; RNA IP was assayed as in (A). These data show the means 6 SD from three independent experiments. (C) ChIP assay using an anti-SUZ12
antibody in HeLa cells overexpressing ANRASSF1 (pCEP4 ANRASSF1, black bars) or control cells (empty pCEP4, white bars). The promoter regions of
the RASSF1A and RASSF1C isoforms and two other genes on either side of the RASSF1 locus on chr 3 were investigated (the promoters are indicated
with vertical lines in the scheme shown at the bottom of the figure). Control GAPDH was included as a gene not expected to be regulated through
SUZ12. Control HOXA9 is a gene regulated through SUZ12 [34] and encoded on chr 7. The amount of DNA in anti-SUZ12 samples at each promoter
region detected through qPCR analysis was calculated in relation to the input. These data show the means 6 SD from three independent
experiments. *t-test p,0.02 relative to control at the RASSF1A locus. No significant changes were detected at other loci. (D) ChIP analysis using an
anti-H3K27me3 antibody in an assay similar to that described in (C), except that the enrichment was calculated relative to anti-H3 ChIP. These data
show the means 6 SD from three independent experiments. *t-test p,0.02 relative to control at the RASSF1A locus. No significant changes were
detected at the other loci. (E) ChIP analysis using an anti-DNMT3B antibody in an assay similar to that described in (C). These data show the means 6
SD from three independent experiments. No significant change was observed. (F) DNA methylation at the RASSF1A promoter region was detected
through qPCR with a methylation-dependent McrBC endonuclease assay in the ANRASSF1-overexpressing or control cells. The percentage of DNA
remaining was calculated after comparing the amount of DNA amplified through qPCR following treatment with McrBC endonuclease with that
following no-endonuclease treatment. These data show the means 6 SD from three independent experiments. No significant change was observed.
doi:10.1371/journal.pgen.1003705.g006
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ANRASSF1 is an unspliced intronic lncRNA and a member of a
poorly characterized class of RNAs, as intronic unspliced RNAs
are occasionally suspected as technical artifacts or transcriptional
noise [39]. Notably, the intronic ANRASSF1 in HeLa cells showed
considerably lower expression levels compared with the well-
studied intergenic lncRNAs (Figure S2). Nevertheless, changes in
ANRASSF1 abundance through ectopic overexpression or siRNA-
mediated knockdown have specifically affected RASSF1A gene
expression through PRC2 recruitment. Most importantly, the
changes in ANRASSF1 abundance did not affect the expression of
RASSF1C, another mRNA isoform expressed in the RASSF1 locus
under a different promoter, or the levels of H3K27me3 and PRC2
recruitment to the RASSF1C promoter and the promoters of
neighboring genes in the RASSF1 locus, including two other well-
characterized tumor suppressor genes, namely TUSC2 [32] and
NPRL2 [33]. These data suggest a highly location-specific
epigenetic regulation at the histone level that is driven by lncRNA
ANRASSF1.
DNA methylation of the RASSF1A promoter involves PRC2 and
DNMT3B DNA-methyl transferase in lung carcinoma cell lines
that have high HOX3B expression [10]. We observed a
limited, non-significant effect on DNA methylation at the
RASSF1A promoter when the PRC2 occupancy was changed
through ANRASSF1 overexpression or knockdown in HeLa
cells. Other factors, such as HOXB3 expression and DNMT3B
occupancy at the RASSF1A promoter, are involved in DNA
methylation [10], and the observed limited increase in DNA
methylation in HeLa cells overexpressing ANRASSF1 might
reflect the eventual limited availability of these factors in HeLa
cells. Indeed, the promoter region of RASSF1A in HeLa cells is
hypomethylated [3].
Recently, many intronic RNA sequences capable of binding the
PRC2 core component EZH2 have been detected in human
cancer cells [20]. These authors characterized an EZH2-bound
intronic unspliced RNA for the methyltransferase gene SMYD3 in
more detail and observed that EZH2 binds to sense intronic
ncRNA either at the pre-mRNA stage or after splicing and intron
removal [20]. The overexpression of sense ncRNA from the
SMYD3 locus caused the epigenetic in cis regulation of SMYD3 and
a decrease in cell proliferation [20]. Different from ANRASSF1, this
Figure 7. ANRASSF1mediates recruitment of SUZ12 to the RASSF1A promoter. (A) RNase assay for detection of ANRASSF1 using RT-qPCR in
permeabilized HeLa cells treated with RNase inhibitor (black bar), RNase H (red bar) or RNase A (blue bar). RNA% for each of the two RNase
treatments was calculated relative to the corresponding values for the RNase inhibitor. These data show the means 6 SD from three independent
experiments. (B) As a control, alpha-tubulin mRNA was measured using RT-qPCR in parallel under the same conditions as described in (A). These data
show the means6 SD from three independent experiments. (C) RNase-ChIP assay with anti-SUZ12 antibody in permeabilized HeLa cells treated with
either RNase inhibitor (black bar), RNase H (red bar) or RNase A (blue bar). The amount of DNA at the RASSF1A promoter region detected through
qPCR in anti-SUZ12 samples was calculated in relation to the input. These data show the means 6 SD from two independent experiments that were
performed in triplicate. (D) The amount of DNA at the RASSF1C promoter region was measured under the same conditions as described in (C). (E–F)
The amount of DNA at the RASSF1A and RASSF1C promoter regions was measured under the same conditions as in (C–D), except that an anti-
DNMT3B antibody was used. (G–H) The amount of DNA at the RASSF1A and RASSF1C promoter regions was measured under the same conditions as
in (C–D), except that an anti-RNA Pol II antibody was used.
doi:10.1371/journal.pgen.1003705.g007
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intronic unspliced lncRNA is not derived from an independent
transcriptional unit in the locus.
Another example of intronic unspliced lncRNA recruiting
PRC2 is Kcnq1ot1, which is transcribed from the Kcnq1 locus. The
lncRNA Kcnq1ot1 regulates the expression of ten genes at the Kcnq1
imprinted cluster [40] through a mechanism clearly distinct from
the location-specific cis-acting regulation of the RASSF1A isoform
observed here.
In the present study, we demonstrated that the unspliced
intronic ANRASSF1 binds to PRC2 and is required for PRC2
occupancy at the RASSF1A promoter region. We postulate an in cis
mechanism (Figure 9) by which the interaction of ANRASSF1 with
both DNA at its transcription site and PRC2 induces the
recruitment of PRC2 to the RASSF1A and not the RASSF1C
promoter. In turn, PRC2 recruitment induces the accumulation of
the repressive mark H3K27me3, which culminates in the
transcriptional down-regulation of only the RASSF1A isoform
(Figure 9). This model, which involves a lncRNA/DNA hybrid,
would be analogous to that of the intergenic lncRNA Mistral;
however, different from the model proposed here, the intergenic
Figure 8. PRC2 is specifically directed by ANRASSF1 lncRNA to the RASSF1A promoter. (A) ChIP assay using an anti-SUZ12 antibody in HeLa
cells transfected with an RNAi oligonucleotide antisense to ANRASSF1 or with a control scrambled oligonucleotide. The amount of DNA at the
RASSF1A promoter region detected using qPCR in the anti-SUZ12 samples was calculated in relation to the input. These data show the means 6 SD
from two independent experiments performed in triplicate. *p,0.03 relative to control. (B) ChIP assay using an anti-DNMT3B antibody in an assay
similar to (A). (C) DNA methylation at the RASSF1A promoter region was detected through qPCR in a methylation-dependent McrBC endonuclease
assay in cells transfected with an RNAi oligonucleotide antisense to ANRASSF1 or with a control scrambled oligonucleotide. The percent remaining
DNA was calculated by comparing the amount of DNA at the promoter of RASSF1A amplified through qPCR following treatment with McrBC
endonuclease against that amplified in the no-endonuclease treatment. These data show the means 6 SD from three independent experiments. No
significant change was observed.
doi:10.1371/journal.pgen.1003705.g008
Figure 9. Proposedmodel for ANRASSF1 function at the RASSF1 genomic locus.We postulate that lncRNA ANRASSF1 (blue line) interacts with
genomic DNA at the transcription site, forming an RNA/DNA hybrid, and recruits the chromatin-modifying PRC2 complex to the protein-coding
RASSF1A gene promoter region. The recruitment of the PCR2 complex results in the selective modification of the histone H3K27 pattern of
methylation (red circles) at the RASSF1A promoter, leading to a specific reduction in RASSF1A transcriptional activity with no effect on the RASSF1C
transcription.
doi:10.1371/journal.pgen.1003705.g009
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lncRNA Mistral mediates the activation of HOXA6 and HOXA7
transcription in trans [36]. The MLL1 SET domain is involved in
recognizing and binding the Mistral/DNA hybrid, thus triggering
dynamic changes in the chromosome conformation [36] that
involve the formation of a loop in the DNA at the promoter of the
HOXA6 and HOXA7 neighboring genes. A loop conformation at
the RASSF1A promoter, similar to that proposed for the Mistral
locus, could be the subject of further investigation.
ANRASSF1 is one of the thousands of unspliced lncRNAs,
named TIN and PIN RNAs, transcribed from the intronic regions
of 74% of the protein-coding genes in the human genome [22,41].
The formation of an RNA/DNA hybrid at the transcription locus
could result in a highly location-specific effect for a number of
these unspliced intronic lncRNAs. Indeed, 141 lncRNAs map to
the intronic regions of 127 protein-coding genes and are associated
with chromatin, as identified through chromatin-RNA isolation
and high-throughput sequencing [42]; of these, 52% are TIN/PIN
RNAs [42]. We hypothesize that other non-characterized un-
spliced intronic lncRNAs transcribed in the human genome might
contribute to a diverse location-specific epigenetic modulation at
the loci where they are transcribed [43].
There is increasing evidence that lncRNAs are involved in a
number of human diseases [44–46], particularly in cancer [46–
50]. Taken together, our results reveal a novel mechanism for
epigenetic regulation at the RASSF1 locus that involves the
antisense unspliced lncRNA ANRASSF1, suggesting an inverse
correlation between ANRASSF1 and RASSF1A expression in both
tumor and non-tumor cell lines. Further studies on the potential
involvement of ANRASSF1 expression in tumorigenesis are
warranted. These results could be the tip of the iceberg of an
epigenetic modulation mechanism driven through unspliced
intronic lncRNAs that might act at highly gene-specific loci in
the human genome.
Materials and Methods
Cell lines and RNA extraction
All cell lines were obtained from the American Type Culture
Collection (ATCC) and grown as recommended in media
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin (Gibco). Total RNA was extracted using Trizol
(Invitrogen) and purified using the RNAspin Mini kit (GE
Healthcare) according to the manufacturer’s instructions, except
for an extended 1 h treatment with DNase I. Total RNA was
quantified on a NanoDrop ND-1000 Spectrophotometer (Nano-
Drop Technologies). Total RNA integrity was assessed using an
Agilent 2100 Bioanalyzer (Agilent Technologies).
RACE and primer-walking PCR
For RACE-PCR, we used a commercial Human Colon
Marathon-Ready cDNA library (Clontech) prepared from poly(A)
RNA and Advantage 2 polymerase (Clontech) according to the
manufacturer’s instructions. Primer-walking PCR, using the
sequence obtained from the in silico prediction of the transcrip-
tional start site (TSS), was performed as described in the
supporting information (Protocol S1). All primers are listed in
Table S1. The PCR products were sequenced using the Sanger
method. The ANRASSF1 full-length sequence has been deposited
in GenBank under accession number KC330992.
Strand specific RT–PCR
Orientation-specific RT-PCR was performed with 1.5 mg total
RNA using a gene-specific primer complementary to the antisense
or sense strand of ANRASSF1 according to the recommendations
of Super Script III kit protocol (Invitrogen). Subsequently, PCR
was performed using the internal primer pair indicated in
Figure 1B. The primers are listed in Table S1. To control for
DNA contamination in the RNA sample, reverse transcription
with no RT-primer was performed, followed by PCR.
Reverse transcription and quantitative real-time PCR
(RT-qPCR)
Oligo-dT-primed reverse transcription (RT) was performed
using 1 mg of total RNA according to the Super Script III kit
protocol (Invitrogen). The relative levels of the ANRASSF1 and
RASSF1 isoforms and other lncRNAs were determined through
quantitative real-time PCR (qPCR) (primers are shown in Table
S2) with Power SYBR Green (Applied Biosystems) using the 7500
Real Time PCR System (Applied Biosystems). The levels of these
transcripts were normalized to the level of tubulin and represented
as a fold-change using the delta Ct method [51].
RNA-seq
Poly(A)+-RNA was extracted from LNCaP cells in culture using
the FastTrack MAG Maxi mRNA Isolation Kit (Invitrogen)
according to the manufacturer’s instructions with the following
modifications: treatment with 25 U of amplification grade DNase
I (Invitrogen) for 1 h at room temperature. RNA was quantified
using the Quant-iT RiboGreen RNA Reagent (Invitrogen) and
assessed for integrity through electrophoresis with the Bioanalyzer
RNA Pico LabChip (Agilent Technologies). Poly(A)+-RNA from
three biological replicates was processed for Illumina sequencing
using the standard protocol for strand-oriented paired-end 75-nt
read sequencing, and a total of ,430 million reads were obtained
and mapped with TopHat [52] to the hg19 version of the human
genome, followed by an ab-initio assembly using the Cufflinks tool
[53], with the default parameters.
Meta-analysis of the Affymetrix microarray expression
data
A meta-analysis was performed using the publicly available
microarray expression data from the Affymetrix HG-U133 Plus2
platform. The purification strategy, RNA processing method and
hybridization strategy have been described in the original
publications. The expression and sample annotation data were
downloaded from the NCBI GEO website: GSE5823 [54],
GSE11118 [55], GSE10879 [56], GSE12056 [57] and
GSE13471 [58]. A Pearson correlation analysis between the
expression signals of probe sets 240278_at (ANRASSF1) and
204346_s_at (RASSF1 entire locus) was used in each study.
ANRASSF1 overexpression and silencing
For overexpression, the ANRASSF1 cDNA was amplified
through PCR (primers in Table S1), inserted into the pCEP4
expression vector (Invitrogen) to generate pCEP4 ANRASSF1 and
subsequently sequenced. The cells were transfected with a
linearized pCEP4 ANRASSF1 or a linearized empty vector (NheI)
using FuGENE 6 Transfection Reagent (Roche). After transfec-
tion, the resistant cells were selected using 100 mg/mL hygromycin
B (Invitrogen). For silencing, the HeLa cells were plated on 60-mm
plates in medium without FBS. Twenty-four hours after plating, a
pool of three distinct 25-mer siRNAs (5 nM each, final concen-
tration) targeting ANRASSF1 or a pool of three 25-mer scrambled
siRNAs (Invitrogen) (Table S3) were transfected using Lipofecta-
mine RNAimax (Invitrogen). The total RNA was extracted at 48 h
after transfection. Alternatively, 120 nM of a modified 20-mer
oligo (Table S3) was used for ANRASSF1 silencing in the ChIP
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assays, which were performed at 24 h after transfection using
Lipofectamine RNAimax (Invitrogen).
Western blotting
The cells were washed with PBS, lysed on ice in 20 mM
imidazole (pH 7.2) containing 1 mM EDTA and 250 mM sucrose
with complete protease inhibitor cocktail (Roche) and sonicated.
The protein content in the lysates was determined using the BCA
protein assay (Bio-Rad). Equal protein amounts (40 mg) were
resolved through SDS-PAGE. The primary antibodies were anti-
RASSF1A (Abcam – ab23950) and anti-actin (Millipore –
mab1501); and secondary antibodies were labeled with Alexa
Fluor 680 (Invitrogen). The signals were detected using an
Odyssey Infrared Imaging System (LI-COR Biosciences). The
signal intensities were quantified using Odyssey Application
Software v3 (LI-COR Biosciences).
Cell proliferation assay
HeLa cells transfected with empty pCEP4 or pCEP4 ANRASSF1
were seeded onto 96-well plates. Each pair of biological replicates
was seeded onto the same plate. Cell proliferation was evaluated in
an MTS assay by measuring formazan absorbance at 24 and 48 h
using the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega) in a SpectraMax Paradigm (Molecular Devices).
Three independent replicate transfections were tested. The
proliferation coefficient was defined as the ratio between the
average measurements at 24 and 48 h. For the RNAi assay, HeLa
cells were seeded onto 96-well plates in media without FBS. The
transfections were performed at 24 h after the seeding, and the
cells were evaluated for proliferation at 24 and 48 h, as described
above.
Population doubling time
To measure the effect of ANRASSF1 overexpression on the
cellular proliferation phenotype, 26104 cells overexpressing
ANRASSF1 or control cells were seeded onto a 6-well plate. The
cells were trypsinized every 24 h for 5 days and counted on a
Neubauer chamber. The adjustment of exponential functions to
the curves and statistical analyses were performed using GraphPad
Prism software.
Analyses of the sub-G1 population after UV irradiation
To measure the UV-induced sub-G1 population, which is
indicative of cell death, plates containing pre-seeded cells at 70%
confluence were washed with PBS and irradiated with 40 J/m2
UVC light with a germicidal lamp (primary emission at 254 nm) at
a rate of 1.0 J.m22.s21, as measured with a VLX 3W radiometer
(Vilber Lourmat). After 48 h, the supernatant and the attached
cells were collected and fixed with 70% ethanol. Staining with
propidium iodide (PI) was performed at room temperature for 1 h
in PBS solution containing 20 mg/mL PI (Sigma-Aldrich), 200 mg/
mL RNase A (Invitrogen) and 0.1% Triton X-100 (Sigma-
Aldrich). These samples were loaded onto a Guava PCA-96
System cytometer (Millipore), and the analyses were performed
using CytoSoft software (Millipore).
Staurosporine-induced cytotoxicity assay
The cytotoxicity induced through staurosporine treatment was
evaluated with a real time cytotoxicity assay using the xCELLi-
gence system (Roche). Briefly, 26103 cells overexpressing
ANRASSF1 or control cells were seeded in triplicate onto the wells
of a 96-well E-plate (Roche). After 18 h, these samples were
treated with 100 nM staurosporine (Sigma) or mock-treated with
the same concentration of DMSO (zero time). Thereafter, the
impedance was continuously measured according to the manu-
facturer’s instructions and as previously described [59]. Three
independent biological replicate experiments were performed,
each with technical triplicates.
RNA Immunoprecipitation (RIP)
Native, non-cross linked RIP was performed using the Magna
RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore)
according to the manufacturer’s instructions. The following
antibodies were used from Millipore: Normal Mouse IgG (12-
371) and anti-SUZ12 (03-179); and Abcam: anti-EZH2 (ab3748).
The RNAs were extracted using Trizol, treated with TURBO
DNase (Ambion) at 37uC for 30 min, purified using an RNeasy
Micro Kit (Qiagen) and quantified with RiboGreen (Invitrogen).
All RIP assays were performed in biological triplicate and were
detected by RT-qPCR (primers in Table S2).
Chromatin Immunoprecipitation (ChIP)
ChIP was performed using the EZ-Magna ChIP Chromatin
Immunoprecipitation Kit (Millipore). The following antibodies
were used from Millipore: normal mouse IgG (12-371), normal
rabbit IgG (12-370) and anti-SUZ12 (03-179); and Abcam: anti-
H3K27me3 (ab6002), anti-H3 (ab1791) and anti-DNMT3B
(ab2851). The DNA was detected through qPCR (primers in
Table S2).
RNase ChIP
Permeabilization of HeLa cells and RNase treatment were
performed as previously described [36]. After the RNase
treatment, an aliquot (70% vol) was processed as described
above in the ChIP protocol using the following antibodies
from Millipore: normal mouse IgG (12-371), anti-SUZ12 (03-
179) and anti-RNA Pol II clone CTD4H8 (05-623B); and
Abcam: anti-DNMT3B (ab2851). The remaining aliquot (30%
vol) was processed as described in the RNA extraction
protocol and analyzed through RT-qPCR (the primers are
listed in Table S2).
DNA methylation assay
DNA was extracted using phenol/chloroform and Proteinase K
using a previously published method [60] and fragmented through
sonication. A 1-mg sample of this DNA was treated with 100 U of
methylation-dependent McrBC endonuclease (New England
Biolabs) at 37uC for 16 h. The amount of RASSF1A promoter
DNA was measured using qPCR (primers in Table S2). As a
control, an assay with no endonuclease was run in parallel. Three
biological replicates were tested.
Supporting Information
Figure S1 Negative correlation between ANRASSF1 and RASSF1
expression levels in cell lines and human tissues. Meta-analysis
results from (A) MCF-7 cells, wild-type and estrogen-deprived cells
from GSE10879 [56]; (B) K562 cells, wild-type and CREB-
knockdown cells from GSE12056 [57]; and (C) colon tumor,
normal colon and normal liver human tissues from GSE13471
[58].
(TIF)
Figure S2 ANRASSF1 lncRNA is RNAPII-encoded and nuclear-
enriched and has a short half-life. (A) ANRASSF1 is transcribed
through RNA Polymerase II (RNAPII). HeLa cell cultures were
treated with the RNAPlI inhibitor a-amanitin (black) or with
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vehicle (mock, gray) for 24 h. The ANRASSF1 transcript
abundance before and after a-amanitin treatment was measured
with RT-qPCR. The results were normalized using the level of
pre-tRNATyr, transcribed through RNAPIII and plotted relative
to the mock condition. RNAPII-transcribed a-tubulin is shown
as a positive control. These data show the means 6 SD from
three independent experiments. *p,0.0001. (B) Presence of a
59-end cap modification in ANRASSF1. Total RNA from HeLa
cells was digested using the terminator 59-phosphate-dependent
exonuclease (59 exo) alone or in combination with the tobacco
acid pyrophosphatase (TAP) as indicated. Subsequently, the
samples were reverse transcribed and used as a template for
qPCR with primers for ANRASSF1, a-tubulin (positive control) or
snRNA U15A, which does not have a 59cap (negative control),
as indicated. (C) Decay of ANRASSF1 RNA in the presence of
actinomycin D. HeLa cells were treated with the transcriptional
inhibitor actinomycin D or vehicle for 0,1, 3, 6 and 8 h. At each
time point, total RNA was isolated, and the ANRASSF1 and c-
Myc levels were measured using RT-qPCR, and normalized to
that of an untreated sample. These data show the means 6 SD
from two independent experiments in triplicate. The insets show
parameters for the fitted curves using one-phase exponential
decay. (D) The relative abundance of the ANRASSF1 RNA
transcript in the nuclear or cytoplasmic compartments. Cellular
fractions enriched in the nuclear or cytoplasmic RNAs were
prepared from HeLa cells. Comparable starting amounts of
RNA from each fraction were used for oligo-dT primed reverse
transcription reactions, followed by qPCR with primers for
ANRASSF1. These data show the means 6 SD from two
independent experiments in triplicate. (E) Expression levels of
some selected abundant intergenic lncRNAs and RASSF1 main
isoforms relative to ANRASSF1. Gene expression was measured
in HeLa cells through RT-qPCR and normalized to ANRASSF1.
These data show the means 6 SD from three independent
experiments.
(TIF)
Figure S3 A putative ANRASSF1 promoter region shows activity
in the luciferase assays. (A) Genomic localization of the constructs
spanning the putative antisense promoter region of ANRASSF1
(antisense promoter, solid gray DNA on the plus strand) and the
putative sense promoter region of RASSF1C (sense promoter, solid
gray DNA on the minus strand) used in the promoter activity
luciferase assays. The arrows indicate the orientation of the
ANRASSF1 lncRNA and the protein-coding transcripts in the
locus. (B) Promoter activity measured using the firefly luciferase
assay. HeLa cells were transfected with pGL3 vectors harboring
different constructs upstream of the firefly luciferase gene as
indicated. Cells transfected with pGL3 empty (negative control) or
pGL3 SV40 promoter plasmids (positive control) were assayed in
parallel. These data show the means 6 SD from three
independent experiments. *p,0.01.
(TIF)
Figure S4 Endogenous ANRASSF1 interaction with PRC2. (A)
Endogenous levels of ANRASSF1 bound to PRC2 were measured
in HeLa cells through RNA IP using an anti-EZH2 antibody, and
the results were referred to as % input. The IgG from non-
immunized mouse was included as a control. The asterisk indicates
non-detectable amounts. (B) The level of lincRNA SFPQ, which
does not bind to the PRC2 complex, as determined using anti-
SUZ12 and anti-EZH2 antibodies [18], was measured as a
positive control. These data show the means 6 SD from three
independent experiments.
(TIF)
Figure S5 ANRASSF1 mediates the recruitment of SUZ12 to
the RASSF1A promoter region in HeLa cells overexpressing
ANRASSF1. (A) RNase-ChIP assay for the RASSF1A promoter
region measured through qPCR in DNA immunoprecipitated
using an anti-SUZ12 antibody in permeabilized HeLa cells
overexpressing ANRASSF1. The cells were treated with either
RNase inhibitor (black bar), RNase H (red bar) or RNase A
(blue bar). The amount of DNA at the RASSF1A promoter
region detected through qPCR in anti-SUZ12 samples was
calculated in relation to the input. These data show the means
6 SD from two independent experiments in triplicate. (B)
Detection of ANRASSF1 using RT-qPCR with samples obtained
from HeLa cells overexpressing ANRASSF1 and previously
permeabilized and treated with RNase inhibitor (black bar),
RNase H (red bar) or RNase A (blue bar). The RNA% for each
of the two RNase treatments was expressed relative to the
corresponding values for RNase inhibitor. These data show the
means 6 SD from three independent experiments. (C) As a
control, alpha-tubulin mRNA was measured in parallel with RT-
qPCR under the same conditions as described in (B). These data
show the means 6 SD from three independent experiments.
(TIF)
Protocol S1 Materials and methods for RACE and primer-
walking PCRs, 59-cap analysis, RNA polymerase transcription
inhibition, cell fractionation and the promoter assay.
(DOC)
Table S1 Primers used for strand-specific RT, cloning, 59-cap
assay, RACE and primer walking.
(DOC)
Table S2 Primers used for qPCR, ChIP, RIP, RNase-ChIP and
methylation assays.
(DOC)
Table S3 Oligonucleotide sequences used for knockdown assays.
(DOC)
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